The global pharmaceutical industry experienced a 19% drop in company filings mentions of future of work in Q2 2023 compared with the previous quarter, with the highest share accounted for by WuXi Biologics Cayman with 57% year-on-year increase, according to GlobalData’s analysis of over 423 pharmaceutical company filings. GlobalData’s Future of Work – Thematic Research report explains how the theme future of work is impacting the workforce across different sectors, it presents key technology, macroeconomic and regulatory trends, market size and growth forecasts for technologies that will play a key role in the theme. Buy the report here.
Notably, future of work was one of the most frequently referenced themes in Q2 2023, ranking highest in terms of mentions, ahead of immuno-oncology and environment, according to GlobalData.
Of the top leading companies in the pharmaceutical industry, WuXi Biologics Cayman had the greatest increase in references for future of work in Q2 2023, compared with the previous quarter. GlobalData identified 11 future of work-related sentences in the company's filings - 0.3% of all sentences - and an increase of 57% in Q2 2023 compared with Q2 2022. Amgen’s mentions of future of work rose by 250% to 7 and Merck’s by 40% to 7 and Biogen’s by 14% to 6 and Recordati’s by 64% to 5.
GlobalData’s Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative, or neutral. Starting at 100 in 2020, an index over 100 is more positive. The overall index for future of work in Q2 2023 was 96.
For further understanding of GlobalData's Future of Work – Thematic Research buy the report here.